Illumina, Inc. (NASDAQ:ILMN) Stake Lowered by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,862 shares of the life sciences company’s stock after selling 5,915 shares during the period. Public Employees Retirement System of Ohio’s holdings in Illumina were worth $7,546,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ILMN. Bank of New York Mellon Corp grew its stake in shares of Illumina by 7.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after buying an additional 204,043 shares in the last quarter. Primecap Management Co. CA lifted its stake in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after acquiring an additional 87,599 shares during the last quarter. Janus Henderson Group PLC grew its position in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares in the last quarter. Millennium Management LLC increased its stake in shares of Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after purchasing an additional 1,118,747 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Illumina by 4.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after purchasing an additional 54,319 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a report on Wednesday, August 28th. Robert W. Baird lifted their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Barclays upped their price objective on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Finally, Leerink Partners upped their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Nine equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average target price of $165.86.

Illumina Stock Down 0.8 %

Shares of Illumina stock opened at $146.43 on Friday. The business has a fifty day simple moving average of $144.02 and a 200 day simple moving average of $127.89. The stock has a market cap of $23.22 billion, a PE ratio of -14.70 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 EPS. Research analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.